Funding for this research was provided by:
National Natural Sciences Foundation Key Program (81630071)
CAMS Innovation Fund for Medical Sciences (2016-I2M-3-008)
Aiyou Foundation (KY201701)
Ministry of Education Innovation Team development project (IRT-17R10)
CAMS Key lab of translational research on lung cancer (2018PT31035)
China National Natural Sciences Foundation (81871889)
National Key R&D Program of China (2019YFC1315700)
Received: 22 February 2020
Accepted: 2 July 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: Samples for the 89 early-stage NSCLC patients and 73 advanced NSCLC patients from ZS immunotherapy cohort were procured under the protocol by the ethics committees of the National Cancer Center and the ethical review board of Sun Yat-sen University Cancer Center. The ethics approval number for this study is: NCC2018-092.
: No potential conflicts of interest were disclosed by the authors.